cusabio2015的部落格

Led by Barry McColl from the University of Edinburgh, a study now provides an explanation for why individuals who have stroke are susceptible to serious infections that may lead to death. (Cusabio offers NES Monoclonal Antibody.)

Stroke is one of the most prevalent causes of death and disability worldwide. The World Health Organization estimates that stroke and heart disease are responsible for a combined 15 million deaths in 2015. One major complication of acute stroke is infection, which results in elevated mortality. Currently, treatment does not focus on combating infection in part because why stroke patients are susceptible to infections remains a elusive.

Abnormal accumalation of tau protein in the brain has been linked to various neurodegenerative diseases like Alzheimer's disease (AD) and chronic traumatic encephalopathy. The harmful protein aggregates can result in memory loss, confusion and even aggressive behavior. These diseases are called tauopathies. Currently, no simple test is available to identify whether individuals' symptoms are associcated with tau accumulation in the brain.

Now a new study, published in the latest version of the journal Science Translational Medicine and led by Washington University in collaboration with the University of California, has shown that antibodies can capture tau in the blood. This may aid in developing tools for measurement of tau levels.

The protein lysyl oxidase (LOX) is an extracellular copper-dependent enzyme that functions in the crosslinking of collagens and elastin. Due to this function, LOX can remodel the tumor microenvironment. Previous research has shown that upregulation of LOX appears to promote tumor growth and metastasis and is associated with poor outcome in colon, breast, pancreas, prostate and lung cancers. (Cusabio provides LOX, EGFR, and Recombinant GGCX.)

Now researchers from the University of Manchester and The Institute of Cancer Research have identified a new pathway by which LOX uses to drive tumor progression. The have described their findings in Nature Communications. The paper “Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface” reports that LOX regulates the a transmembrane protein called epidermal growth factor receptor (EGFR). Like LOX, EGFR is also linked to tumor growth and spread.

Study reveals that stabilizing a specific protein could help to treat spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and possibly other motor neuron diseases. (Cusabio provides SMN and Recombinant HTR1B.)

SMA results from a deficiency of survival motor neuron (SMN) protein due to mutations in the SMN1 gene. The deficiency leads to degeneration of motor neurons and atrophy of skeletal muscle. The severity of disease symptoms varies greatly from individual to individual. Milder forms of SMA can cause movement problems, while more severe forms can cause paralysis and even death. Currently, there is no effective therapy for SMA, and treatment is usually limited to supportive care.

Scientists have found that some diagnostic tools are not accurate enough when it comes to children with impaired kidney function, according to a study published in the Journal of Applied Laboratory Medicine.

The paper "Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children" shows that diagnostic disease markers may be influenced by the renal function.

Immunotherapy has emerged as a useful treatment option for various cancers and some other disesases. However, cancer cells may utimately develop resistance to this treatment. It we can find ways to prevent this from happening or to solve it, it will greatly improve the effectiveness of immunotherapy.

In a tumor, new blood vessels are generated, and these blood vessels offer oxgen and nutrients that maintain the survival and growth of the tumor cells. These tumor blood vessels also prevent T cells from reach the tumor cells, which protects the tumor cells from the effects of the immune system and immunotherapies. VEGFA and ANGPT2 are two major proteins that are involved in the growth of tumor blood vessels and inhibiting T cell response.

As the leading cause of senile dementia, Alzheimer’s disease (AD) constitutes a big burden on the health care system and causes much pain to the patients and their families. The prevalence of AD is expected to triple by the year 2050. A growing body of evidence suggests that AD is associated with protein misfolding and aggregation in the brain, such as accumulation of amyloid and tau.

Previous studies have linked midlife vascular risk factors such as obesity, high blood pressure, diabetes, high cholesterol and smoking to late-life dementia. But whether these factors directly contribute to brain amyloid deposition remains a mystery. Now, a study appearing in JAMA shows that many midlife vascular risk factors indeed associated with with elevated brain amyloid.

New research shows that activation of STAT5 causes competition among other proteins, leading to an imbalance that increases the risk of acute lymphoblastic leukemia (ALL). (STAT5 and other other proteins like Recombinant NFE2L1 can be offered by Cusabio.)

The paper, titled “Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival”, appears in the journal Nature Immunology.

Pancreatic cancer is basically a hard-to-treat disease. As the fourth leading cause of cancer deaths, pancreatic cancer is blamed for 7% of all cancer-related deaths. Pancreatic ductal adenocarcinoma (PDA), the predominant form of pancreatic cancer, makes up the vast majority of all pancreatic cancer cases. 

Now an article “Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance” published online 10 April 2017 in Nature Medicine reveals a mechanism that PDA uses to escape the body’s immune attack. This will lead to a new strategy for developing immunotherapies for the fatal disease. George Miller at the New York University School of Medicine is the senior author of the article.

An antibody provides great protection against radiation-induced pulmonary fibrosis, researchers report in Journal of the National Cancer Institute. The study is a collaboration of the German Cancer Research Center, University Hospital Center, and FibroGen, Inc.. (Cusabio provides various proteins and antibodies such as PODXL Monoclonal Antibody.)

Radiotherapy is an important treatment option for patients with cancer. In fact, nearly two thirds of cancer patients will receive radiotherapy. For this, radiotherapy often claimed to be orthodox medicine’s number 1 weapon against cancer. In most cases, radiotherapy is effective and well tolerated. However, it has potential side-effects. For example, prolonged exposure to radiation causes the healthy tissue to inflame and eventually scar, a process called fibrosis.